10 recruiting, 6 not yet recruiting, 1 withdrawn. 9 Phase 2, 6 Phase 1, 2 Early Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Not yet recruiting 4 |
| Phase 1 | 6 | Recruiting 4, Not yet recruiting 2 |
| Early Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Multiple Myeloma Refractory: new trials by email Literature Review of Multiple Myeloma Refractory trials Research Report on Multiple Myeloma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-23 | |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma VV169 - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Vyriad, Inc. | 40 | 2026-09-08 | 2026-09-21 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D - Multiple Myeloma Refractory, Multiple Myeloma Progression | Phase 1 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 16 | 2026-06-01 | 2026-06-03 |
| CAR-T in Relapsed/Refractory Multiple Myeloma CAR-T - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-08 |
| Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma Liposomal Curcumin (LipoCurc) - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | University Health Network, Toronto | 20 | 2026-02-27 | 2026-06-12 |
| Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. Autologous BCMA-targeting CAR T cells - Multiple Myeloma in Relapse, Multiple Myeloma Refractory | Phase 1 / Phase 2 | Not yet recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 24 | 2026-02-01 | 2026-02-19 |
| Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Inobrodib, Pomalidomide, Dexamethasone - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | CellCentric Ltd. | 100 | 2026-01-22 | 2026-09-21 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma Teclistamab - Multiple Myleoma, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 52 | 2025-11-01 | 2025-04-03 |
| BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma BCMA/GPRC5D CAR-T - Multiple Myeloma Refractory | Early Phase 1 | Withdrawn | Guangzhou Bio-gene Technology Co., Ltd | 2025-10-10 | 2026-05-28 | |
| Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients HuL001, Lenalidomide/Dexamethasone - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | HuniLife Biotechnology, Inc. | 21 | 2025-08-18 | 2026-09-18 |
| A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) Soursop tea - AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory | Early Phase 1 | Recruiting | Roger Strair | 20 | 2025-06-30 | 2026-08-18 |
| Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma anti BCMA CAR-T cells - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 30 | 2025-02-01 | 2026-10-16 |
Multiple Myeloma (10) · Recurrence (5) · Lymphoma (2) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1) · Neoplasms (1) · Patient Acceptance of Health Care (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Neoplasms by Histologic Type (11) · Blood Protein Disorders (10) · Cardiovascular Diseases (10) · Hemorrhagic Disorders (10) · Hemostatic Disorders (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms, Plasma Cell (10) · Paraproteinemias (10) · Vascular Diseases (10) · Pathologic Processes (6)
Dexamethasone (4) · CCS1477 (2) · pomalidomide (2) · Crossing Over, Genetic (1) · Lenalidomide (1) · Standard of Care (1) · carfilzomib (1) · daratumumab (1) · elotuzumab (1) · tocilizumab (1)
CellCentric Ltd. (2) · CHU de Quebec-Universite Laval (1) · Dr. Zaineb Akram (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Guangzhou Bio-gene Technology Co., Ltd (1) · Hebei Senlang Biotechnology Inc., Ltd. (1) · HuniLife Biotechnology, Inc. (1) · Luminary Therapeutics (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · Odense University Hospital (1) · PETHEMA Foundation (1) · Roger Strair (1) · SCRI Development Innovations, LLC (1) · University Health Network, Toronto (1) · Vyriad, Inc. (1)
United States (5) · Canada (2) · Belarus (1) · Denmark (1) · Pakistan (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Albert Oriol, PhD (1) · Dr Vincent Laroche, MD,FRCPC (1) · Enrique Ocio, PhD (1) · Francesco Zaja (1) · Hans Lee, MD (1) · Jin Lu (1) · Maisie Huang, PhD (1) · Maryam Khan, MBBS, MRCP (UK), FCPS(Cl Haem) (1) · Mikhail Uss, MD (1) · Naseer Qayum (1) · Roger Strair, MD (1) · Tariq Ghafoor (1)